Drug Trial Radar · NCT07766759
A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated Triglycerides
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 25, 2026
Primary completion
Sep 24, 2027
Study completion Dec 20, 2027
Sponsor
- Lead sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effects of a single dose of FXR0906 injection or placebo in Chinese healthy adult volunteers with or without TG increase.
Conditions
- Healthy Adult Volunteers
Interventions
Intervention1: FXR0906 injectionDrug
A single dose of FXR0906 (dose 1 ) will be administered on Day 1 by subcutaneous injection
Intervention2: FXR0906 injectionDrug
A single dose of FXR0906 (dose 2) will be administered on Day 1 by subcutaneous injection
PlaceboDrug
the volume mached placebo is normal saline (0.9%) and will be administered on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- safetyTime frame: through study completion, an average of 26 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.